Live

Endpoints NewsAfter 'redesign,' WuXi Biologics sets new timeline for Massachusetts factory completion BioPharma DiveRegenxbio to resubmit gene therapy as FDA backtracks on another drug rejection Endpoints NewsMapLight to discuss autism drug's future with FDA after Phase 2 miss BioPharma DiveSanofi swaps R&D leaders; Merck’s Prometheus deal pays dividends Endpoints NewsLilly allies with BioArctic; Antengene and Insilico sign deals FierceBiotechIn another reversal for rare disease field, FDA to reconsider Regenxbio gene therapy BioWorldBiggest gainers and losers for June 15-19, 2026 BioWorldHoliday notice Endpoints NewsMerck's IBD drug from $10.8B Prometheus deal claims its first Phase 3 win FierceBiotechMerck’s anti-TL1A antibody from Prometheus buyout passes ph. 3 test in ulcerative colitis PharmaVoicePfizer CFO departs for consumer goods sector FierceBiotechSanofi, Pangaea ink AI partnership deal to detect underdiagnosed genetic disease

Labiotech 22. Juni 2026

8 of the most expensive drugs in biopharma: Unraveling the costliest medications

Find out what the eight most expensive drugs in the world currently are, as several gene therapies top the list. The post 8 of the most expensive drugs in bioph...

Find out what the eight most expensive drugs in the world currently are, as several gene therapies top the list. The post 8 of the most expensive drugs in biopharma: Unraveling the costliest medications appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.